


CLAIMS

What is claimed is:

1. A method of treating ADHD in a mammal suffering therefrom, comprising administering to a mammal in need of such treatment a therapeutically effective amount of an alpha2delta ligand or a pharmaceutically acceptable salt thereof.


2. A compound according to Claim 2, wherein the alpha2delta ligand is gabapentin.

3. The method according to Claim 1, wherein the alpha2delta ligand is a compound of Formula I



and pharmaceutically acceptable salts thereof, wherein R₁ is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

4. The method according to Claim 1, wherein the alpha2delta ligand is a compound of Formula II




and pharmaceutically acceptable salts thereof, wherein:

R₁ is straight or branched unsubstituted alkyl of from 1 to 6 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

R₂ is hydrogen or methyl; and

R₃ is hydrogen, methyl, or carboxyl.

5. The method according to Claim 4, wherein the alpha2delta ligand is pregabalin.
- 5 6. The method according to Claim 4, wherein the alpha2delta ligand is R-(3)-(aminomethyl)-5-methyl-hexanoic acid.
7. The method according to Claim 4, wherein the alpha2delta ligand is 3-(1-aminoethyl)-5-methylheptanoic acid or 3-(1-aminoethyl)-5-methylhexanoic acid.
- 10 8. The method according to Claim 1, wherein the alpha2delta ligand is a compound of the Formula



or a pharmaceutically acceptable salt thereof wherein:

n is an integer of from 0 to 2;

m is an integer of from 0 to 3;

R is sulfonamide,

amide,

5 phosphonic acid,


heterocycle,

sulfonic acid, or


hydroxamic acid;

10 R₁ to R₁₄ are each independently selected from hydrogen or straight or branched alkyl of from 1 to 6 carbons, unsubstituted or substituted benzyl or phenyl which substituents are selected from halogen, alkyl, alkoxy, hydroxy, carboxy, carboalkoxy, trifluoromethyl, and nitro;

A' is a bridged ring selected from



wherein


 is the point of attachment;

Z₁ to Z₄ are each independently selected from hydrogen and methyl;

o is an integer of from 1 to 4; and

5 p is an integer of from 0 to 2 with the proviso that in formula 1 R is not -SO₃H when m is 2 and n is 1.

9. The method according to Claim 8, wherein the alpha2delta ligand is a compound of Formula III



10 and pharmaceutically acceptable salts thereof, wherein:

m is an integer of from 0 to 2;

p is an integer of from 0 to 3; and

R is sulfonamide,

amide,


15 phosphonic acid,

heterocycle,

sulfonic acid, or

hydroxamic acid.


- 20 10. The method according to Claim 8, wherein the alpha2delta ligand is a compound of Formula III



and pharmaceutically acceptable salts thereof, wherein:


m is an integer of from 0 to 2;


p is an integer of 2; and



- 5 11. The method according to Claim 8, wherein the alpha2delta ligand is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, or a pharmaceutically acceptable salt thereof.
12. The method according to Claim 8, wherein the alpha2delta ligand is 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one
- 10 hydrochloride.
13. The method according to Claim 8, wherein the alpha2delta ligand is 3-(1-aminomethyl-cycloheptylmethyl)-4H-[1,2,4]oxadiazol-5-one, or a pharmaceutically acceptable salt thereof.
14. The method according to Claim 8, wherein the alpha2delta ligand is 3-(1-aminomethyl-cycloheptylmethyl)-4H-[1,2,4]oxadiazol-5-one
- 15 hydrochloride.
15. The method according to Claim 8, wherein the alpha2delta ligand is C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, or a pharmaceutically acceptable salt thereof.

16. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine.
17. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is a compound of the Formula III, IIIC, IIIF, IIIG, or IIIH, wherein R is a
5 sulfonamide selected from $-\text{NHSO}_2\text{R}^{15}$ or $-\text{SO}_2\text{NHR}^{15}$ wherein R^{15} is straight or branched alkyl or trifluoromethyl.
18. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is N-[2-(1-aminomethyl-cyclohexyl)-ethyl]-methanesulfonamide.
19. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is a
10 compound of the Formula III, IIIC, IIIF, IIIG, or IIIH wherein R is a phosphonic acid, $-\text{PO}_3\text{H}_2$.
20. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is selected from (1-aminomethyl-cyclohexylmethyl)-phosphonic acid and (2-aminomethyl-4-methyl-pentyl)-phosphonic acid.
21. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is a
15 compound of the Formula III, IIIC, IIIF, IIIG, or IIIH wherein R is a heterocycle selected from





22. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is selected from C-[1-(1H-tetrazol-5-ylmethyl)cyclohexyl]-methanamine and 4-methyl-2-(1H-tetrazol-5-ylmethyl)-pentanamine.

5 23. The method according to Claim 8, wherein the $\alpha_2\delta$ ligand is selected from:

(1-Aminomethyl-cyclohexylmethyl)-phosphonic acid;

(1R-trans)(1-Aminomethyl-3-methyl-cyclohexylmethyl)-
phosphonic acid;

10 (trans)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
phosphonic acid;

(1R-trans)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-
phosphonic acid;

15 (1S-cis)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic
acid;

(1S-trans)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-
phosphonic acid;

(1R-cis)(1-Aminomethyl-3-methyl-cyclopentylmethyl)-phosphonic
acid;

20 (1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
phosphonic acid;

(1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
phosphonic acid;

25 (R)(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-phosphonic
acid;

(S)(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-phosphonic
acid;

- (1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-phosphonic acid;
2-(1-Aminomethyl-cyclohexyl)-N-hydroxy-acetamide;
(1S-trans)2-(1-Aminomethyl-3-methyl-cyclohexyl)-N-hydroxy-
acetamide;
5 (trans)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-hydroxy-
acetamide;
(1S-cis)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-
acetamide;
(1R-trans)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-
10 acetamide;
(1R-cis)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-
acetamide;
(1S-trans)2-(1-Aminomethyl-3-methyl-cyclopentyl)-N-hydroxy-
acetamide;
15 (1 α ,3 α ,4 α)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-
hydroxy-acetamide;
(1 α ,3 β ,4 β)2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-N-
hydroxy-acetamide;
(S)2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-N-hydroxy-
20 acetamide;
(R)2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-N-hydroxy-
acetamide;
2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-N-hydroxy-
acetamide;
25 N-[2-(1-Aminomethyl-cyclohexyl)-ethyl]-methanesulfonamide;
(1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclohexyl)-ethyl]-
methanesulfonamide;
(trans)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-
methanesulfonamide;
30 (1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-
methanesulfonamide;

(1R-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1R-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

5 (1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-methanesulfonamide;

(1 α ,3 α ,4 α)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

10 (1 α ,3 β ,4 β)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(S)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

(R)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-methanesulfonamide;

15 N-[2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-ethyl]-methanesulfonamide;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one;

20 (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

(1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

25 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

(1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

30 (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

(1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;

(S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

(R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

5 3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazole-
5-thione;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-
10 [1,2,4]oxadiazole-5-thione;

(trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

15 (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
20 [1,2,4]oxadiazole-5-thione;

(1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
4H-[1,2,4]oxadiazole-5-thione;

(1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
4H-[1,2,4]oxadiazole-5-thione;

25 (S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

(R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

30 3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

C-[1-(1H-Tetrazol-5-ylmethyl)-cyclohexyl]-methylamine;

- (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclohexyl]-
methanamine;
- (trans)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;
- 5 (1S-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;
- (1R-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;
- (1R-cis)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
10 methanamine;
- (1S-trans)C-[3-Methyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;
- (1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-
cyclopentyl]-methanamine;
- 15 (1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-
cyclopentyl]-methanamine;
- (S)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
methanamine;
- (R)C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclopentyl]-
20 methanamine;
- C-[3,3-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-cyclobutyl]-
methanamine;
- N-[2-(1-Aminomethyl-cyclohexyl)-ethyl]-C,C,C-trifluoro-
methanesulfonamide;
- 25 (1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclohexyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;
- (trans)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-ethyl]-
C,C,C-trifluoro-methanesulfonamide;
- (1R-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-
30 C,C,C-trifluoro-methanesulfonamide;
- (1S-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-
C,C,C-trifluoro-methanesulfonamide;

- (1S-cis)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-
C,C,C-trifluoro-methanesulfonamide;
- (1R-trans)N-[2-(1-Aminomethyl-3-methyl-cyclopentyl)-ethyl]-
C,C,C-trifluoro-methanesulfonamide;
- 5 (1 α ,3 α ,4 α)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-
ethyl]-C,C,C-trifluoro-methanesulfonamide;
- (1 α ,3 β ,4 β)N-[2-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-
ethyl]-C,C,C-trifluoro-methanesulfonamide;
- (S)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-C,C,C-
10 trifluoro-methanesulfonamide;
- (R)N-[2-(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;
- N-[2-(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;
- 15 3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]thiadiazol-5-one;
- (1S-cis)3-(1-Aminomethyl-3-methyl-cyclohexylmethyl)-4H-
[1,2,4]thiadiazol-5-one;
- (trans)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-4H-
[1,2,4]thiadiazol-5-one;
- 20 (1R-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]thiadiazol-5-one;
- (1S-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]thiadiazol-5-one;
- (1S-cis)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
25 [1,2,4]thiadiazol-5-one;
- (1R-trans)3-(1-Aminomethyl-3-methyl-cyclopentylmethyl)-4H-
[1,2,4]thiadiazol-5-one;
- (1 α ,3 α ,4 α)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
4H-[1,2,4]thiadiazol-5-one;
- 30 (1 α ,3 β ,4 β)3-(1-Aminomethyl-3,4-dimethyl-cyclopentylmethyl)-
4H-[1,2,4]thiadiazol-5-one;

(S)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;

(R)3-(1-Aminomethyl-3,3-dimethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;

5 3-(1-Aminomethyl-3,3-dimethyl-cyclobutylmethyl)-4H-[1,2,4]thiadiazol-5-one;

C-[1-(2-Oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;

(1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclohexyl]-methylamine;

(trans)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1S-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

15 (1R-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1R-cis)C-[3-Methyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1S-trans)C-[3-Methyl-1-(2-oxo-2,3-dihydro-

20 2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1 α ,3 α ,4 α)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(1 α ,3 β ,4 β)C-[3,4-Dimethyl-1-(2-oxo-2,3-dihydro-

25 2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

(R)C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-

2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;

C-[3,3-Dimethyl-1-(2-oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclobutyl]-methylamine;

30

- (1-Aminomethyl-cyclohexyl)-methanesulfonamide;
(1R-trans)(1-Aminomethyl-3-methyl-cyclohexyl)-
methanesulfonamide;
(trans)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-
5 methanesulfonamide;
(1S-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-
methanesulfonamide;
(1R-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-
methanesulfonamide;
10 (1R-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-
methanesulfonamide;
(1S-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-
methanesulfonamide;
(1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-
15 methanesulfonamide;
(1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-
methanesulfonamide;
(R)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-
methanesulfonamide;
20 (S)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-
methanesulfonamide;
(1-Aminomethyl-3,3-dimethyl-cyclobutyl)-methanesulfonamide;
(1-Aminomethyl-cyclohexyl)-methanesulfonic acid;
(1R-trans) (1-Aminomethyl-3-methyl-cyclohexyl)-methanesulfonic
25 acid;
(trans)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic
acid;
(1S-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic
acid;
30 (1S-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic
acid;

- (1R-trans)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
- (1R-cis)(1-Aminomethyl-3-methyl-cyclopentyl)-methanesulfonic acid;
- 5 (1 α ,3 β ,4 β)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic acid;
- (1 α ,3 α ,4 α)(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-methanesulfonic acid;
- (R)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonic acid;
- 10 (S)(1-Aminomethyl-3,3-dimethyl-cyclopentyl)-methanesulfonic acid;
- (1-Aminomethyl-3,3-dimethyl-cyclobutyl)-methanesulfonic acid;
- (1-Aminomethyl-cyclopentylmethyl)-phosphonic acid;
- 15 2-(1-Aminomethyl-cyclopentyl)-N-hydroxy-acetamide;
- N-[2-(1-Aminomethyl-cyclopentyl)-ethyl]-methanesulfonamide;
- 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazol-5-one;
- 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]oxadiazole-5-thione;
- 20 C-[1-(1H-Tetrazol-5-ylmethyl)-cyclopentyl]-methylamine;
- N-[2-(1-Aminomethyl-cyclopentyl)-ethyl]-C,C,C-trifluoro-methanesulfonamide;
- 3-(1-Aminomethyl-cyclopentylmethyl)-4H-[1,2,4]thiadiazol-5-one;
- C-[1-(2-Oxo-2,3-dihydro-2 λ^4 -[1,2,3,5]oxathiadiazol-4-ylmethyl)-cyclopentyl]-methylamine;
- 25 (1-Aminomethyl-cyclopentyl)-methanesulfonamide;
- (1-Aminomethyl-cyclopentyl)-methanesulfonic acid;
- (9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-phosphonic acid;
- 2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-N-hydroxy-acetamide;
- 30 N-[2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-ethyl]-methanesulfonamide;

3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-
[1,2,4]oxadiazol-5-one;

3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-
[1,2,4]oxadiazole-5-thione;

5 C-[9-(1H-Tetrazol-5-ylmethyl)-bicyclo[3.3.1]non-9-yl]-
methylamine;

N-[2-(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-ethyl]-C,C,C-
trifluoro-methanesulfonamide;

10 3-(9-Aminomethyl-bicyclo[3.3.1]non-9-ylmethyl)-4H-
[1,2,4]thiadiazol-5-one;

C-[9-(2-Oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-
bicyclo[3.3.1]non-9-yl]-methylamine;

(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-methanesulfonamide;

(9-Aminomethyl-bicyclo[3.3.1]non-9-yl)-methanesulfonic acid;

15 (2-Aminomethyl-adamantan-2-ylmethyl)-phosphonic acid;

2-(2-Aminomethyl-adamantan-2-yl)-N-hydroxy-acetamide;

N-[2-(2-Aminomethyl-adamantan-2-yl)-ethyl]-
methanesulfonamide;

20 3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]oxadiazol-
5-one;

3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]oxadiazole-
5-thione;

C-[2-(1H-Tetrazol-5-ylmethyl)-adamantan-2-yl]-methylamine;

25 N-[2-(2-Aminomethyl-adamantan-2-yl)-ethyl]-C,C,C-trifluoro-
methanesulfonamide;

3-(2-Aminomethyl-adamantan-2-ylmethyl)-4H-[1,2,4]thiadiazol-
5-one;

C-[2-(2-Oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-ylmethyl)-
adamantan-2-yl]-methylamine;


30 (2-Aminomethyl-adamantan-2-yl)-methanesulfonamide;

(2-Aminomethyl-adamantan-2-yl)-methanesulfonic acid

(1-Aminomethyl-cycloheptylmethyl)-phosphonic acid;

2-(1-Aminomethyl-cycloheptyl)-N-hydroxy-acetamide;
 N-[2-(1-Aminomethyl-cycloheptyl)-ethyl]-methanesulfonamide;
 3-(1-Aminomethyl-cycloheptylmethyl)-4H-[1,2,4]oxadiazole-
 5-thione;
 5 N-[2-(1-Aminomethyl-cycloheptyl)-ethyl]-C,C,C-trifluoro-
 methanesulfonamide;
 C-[1-(2-Oxo-2,3-dihydro-2H-[1,2,3,5]oxathiadiazol-4-ylmethyl)-
 cycloheptyl]-methylamine;
 (1-Aminomethyl-cycloheptyl)-methanesulfonamide; and
 10 (1-Aminomethyl-cycloheptyl)-methanesulfonic acid.

24. The method according to Claim 1, wherein the α,δ ligand is a compound of Formula IV



or a pharmaceutically acceptable salt thereof wherein:

- 15 R^1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl;
 R^2 is straight or branched alkyl of from 1 to 8 carbon atoms,
 straight or branched alkenyl of from 2 to 8 carbon atoms,
 cycloalkyl of from 3 to 7 carbon atoms,
 20 alkoxy of from 1 to 6 carbon atoms,
 -alkylcycloalkyl,
 -alkylalkoxy,
 -alkyl OH,
 -alkylphenyl,
 25 -alkylphenoxy,
 -phenyl or substituted phenyl; and

R¹ is straight or branched alkyl of from 1 to 6 carbon atoms or phenyl when R² is methyl.

25. The method according to Claim 24, wherein the alpha2delta ligand is a compound of Formula IV wherein R¹ is hydrogen, and R² is alkyl.
- 5 26. The method according to Claim 24, wherein the Alpha2delta ligand is a compound of Formula IV wherein R¹ is methyl, and R² is alkyl.
27. The method according to Claim 24, wherein the Alpha2delta ligand is a compound of Formula IV wherein R¹ is methyl, and R² is methyl or ethyl.
28. The method according to Claim 24, wherein the alpha2delta ligand is selected from:
- 10
- 3-Aminomethyl-5-methylheptanoic acid;
3-Aminomethyl-5-methyl-octanoic acid;
3-Aminomethyl-5-methyl-nonanoic acid;
3-Aminomethyl-5-methyl-decanoic acid;
15 3-Aminomethyl-5-methyl-undecanoic acid;
3-Aminomethyl-5-methyl-dodecanoic acid;
3-Aminomethyl-5-methyl-tridecanoic acid;
3-Aminomethyl-5-cyclopropyl-hexanoic acid;
3-Aminomethyl-5-cyclobutyl-hexanoic acid;
20 3-Aminomethyl-5-cyclopentyl-hexanoic acid;
3-Aminomethyl-5-cyclohexyl-hexanoic acid;
3-Aminomethyl-5-trifluoromethyl-hexanoic acid;
3-Aminomethyl-5-phenyl-hexanoic acid;
3-Aminomethyl-5-(2-chlorophenyl)-hexanoic acid;
25 3-Aminomethyl-5-(3-chlorophenyl)-hexanoic acid;
3-Aminomethyl-5-(4-chlorophenyl)-hexanoic acid;

3-Aminomethyl-5-(2-methoxyphenyl)-hexanoic acid;
3-Aminomethyl-5-(3-methoxyphenyl)-hexanoic acid;
3-Aminomethyl-5-(4-methoxyphenyl)-hexanoic acid; and
3-Aminomethyl-5-(phenylmethyl)-hexanoic acid.

- 5 29. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is selected from:

(3R,4S)3-Aminomethyl-4,5-dimethyl-hexanoic acid;
3-Aminomethyl-4,5-dimethyl-hexanoic acid;
10 (3R,4S)3-Aminomethyl-4,5-dimethyl-hexanoic acid MP;
(3S,4S)3-Aminomethyl-4,5-dimethyl-hexanoic acid;
(3R,4R)3-Aminomethyl-4,5-dimethyl-hexanoic acid MP;
3-Aminomethyl-4-isopropyl-hexanoic acid;
3-Aminomethyl-4-isopropyl-heptanoic acid;
3-Aminomethyl-4-isopropyl-octanoic acid;
15 3-Aminomethyl-4-isopropyl-nonanoic acid;
3-Aminomethyl-4-isopropyl-decanoic acid; and
3-Aminomethyl-4-phenyl-5-methyl-hexanoic acid.

30. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-heptanoic acid.

- 20 31. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

32. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-nonanoic acid.

- 25 33. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-decanoic acid.

34. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-undecanoic acid.
35. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is (3S,5R)-3-Aminomethyl-5-methyl-dodecanoic acid.
- 5 36. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is selected from:
- 10 (3S,5R)-3-Aminomethyl-5,9-dimethyl-decanoic acid;
(3S,5R)-3-Aminomethyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-5,7-dimethyl-octanoic acid;
(3S,5R)-3-Aminomethyl-5,10-dimethyl-undecanoic acid;
(3S,5R)-3-Aminomethyl-5,8-dimethyl-nonanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclopropyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclobutyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-6-cyclopentyl-5-methyl-hexanoic acid;
15 (3S,5R)-3-Aminomethyl-6-cyclohexyl-5-methyl-hexanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclopropyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclobutyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclopentyl-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-7-cyclohexyl-5-methyl-heptanoic acid;
20 (3S,5R)-3-Aminomethyl-8-cyclopropyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclobutyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclopentyl-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-8-cyclohexyl-5-methyl-octanoic acid;
(3S,5S)-3-Aminomethyl-6-fluoro-5-methyl-hexanoic acid;
25 (3S,5S)-3-Aminomethyl-7-fluoro-5-methyl-heptanoic acid;
(3S,5R)-3-Aminomethyl-8-fluoro-5-methyl-octanoic acid;
(3S,5R)-3-Aminomethyl-9-fluoro-5-methyl-nonanoic acid;
(3S,5S)-3-Aminomethyl-7,7,7-trifluoro-5-methyl-heptanoic acid;

and

(3S,5R)-3-Aminomethyl-8,8,8-trifluoro-5-methyl-octanoic acid.

37. The method according to Claim 24, wherein the $\alpha_2\delta$ ligand is selected from:

5 (3S,5S)-3-Aminomethyl-5-methoxy-hexanoic acid;
(3S,5R)-3-Aminomethyl-8-hydroxy-5-methyl-octanoic acid;
(3S,5S)-3-Aminomethyl-5-ethoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-propoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-isopropoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-*tert*-butoxy-hexanoic acid;
10 (3S,5S)-3-Aminomethyl-5-fluoromethoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-fluoro-ethoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3,3,3-trifluoro-propoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-phenoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-chloro-phenoxy)-hexanoic acid;
15 (3S,5S)-3-Aminomethyl-5-(3-chloro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-chloro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-fluoro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-fluoro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-fluoro-phenoxy)-hexanoic acid;
20 (3S,5S)-3-Aminomethyl-5-(4-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(2-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(3-nitro-phenoxy)-hexanoic acid;
25 (3S,5S)-3-Aminomethyl-5-(2-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-hydroxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-methoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-ethoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-propoxy-hexanoic acid;
30 (3S,5S)-3-Aminomethyl-6-isopropoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-*tert*-butoxy-5-methyl-hexanoic acid;

- (3S,5S)-3-Aminomethyl-6-fluoromethoxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-fluoro-ethoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(3,3,3-trifluoro-propoxy)-hexanoic acid;
5 (3S,5S)-3-Aminomethyl-5-methyl-6-phenoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-chloro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-chloro-phenoxy)-5-methyl-hexanoic acid;
10 (3S,5S)-3-Aminomethyl-6-(2-chloro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-fluoro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-fluoro-phenoxy)-5-methyl-hexanoic acid;
15 (3S,5S)-3-Aminomethyl-6-(2-fluoro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(4-methoxy-phenoxy)-5-methyl-hexanoic acid;
20 (3S,5S)-3-Aminomethyl-6-(3-methoxy-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(2-methoxy-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenoxy)-hexanoic acid;
25 (3S,5S)-3-Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(2-trifluoromethyl-phenoxy)-hexanoic acid;
30 (3S,5S)-3-Aminomethyl-5-methyl-6-(4-nitro-phenoxy)-hexanoic acid;


- (3S,5S)-3-Aminomethyl-5-methyl-6-(3-nitro-phenoxy)-
hexanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-6-(2-nitro-phenoxy)-
hexanoic acid;
- 5 (3S,5S)-3-Aminomethyl-6-benzyloxy-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-7-hydroxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-methoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-ethoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-propoxy-heptanoic acid;
- 10 (3S,5S)-3-Aminomethyl-7-isopropoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-*tert*-butoxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-7-fluoromethoxy-5-methyl-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(2-fluoro-ethoxy)-5-methyl-
- 15 heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-(3,3,3-trifluoro-propoxy)-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-benzyloxy-5-methyl-heptanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-7-phenoxy-heptanoic acid;
- 20 (3S,5S)-3-Aminomethyl-7-(4-chloro-phenoxy)-5-methyl-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(3-chloro-phenoxy)-5-methyl-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(2-chloro-phenoxy)-5-methyl-
- 25 heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(4-fluoro-phenoxy)-5-methyl-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(3-fluoro-phenoxy)-5-methyl-
heptanoic acid;
- 30 (3S,5S)-3-Aminomethyl-7-(2-fluoro-phenoxy)-5-methyl-
heptanoic acid;
(3S,5S)-3-Aminomethyl-7-(4-methoxy-phenoxy)-5-methyl-
heptanoic acid;

- (3S,5S)-3-Aminomethyl-7-(3-methoxy-phenoxy)-5-methyl-heptanoic acid;
- (3S,5S)-3-Aminomethyl-7-(2-methoxy-phenoxy)-5-methyl-heptanoic acid;
- 5 (3S,5S)-3-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenoxy)-heptanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-7-(3-trifluoromethyl-phenoxy)-heptanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-7-(2-trifluoromethyl-phenoxy)-heptanoic acid;
- 10 (3S,5S)-3-Aminomethyl-5-methyl-7-(4-nitro-phenoxy)-heptanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-7-(3-nitro-phenoxy)-heptanoic acid;
- 15 (3S,5S)-3-Aminomethyl-5-methyl-7-(2-nitro-phenoxy)-heptanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;
- (3S,5S)-3-Aminomethyl-6-(4-chloro-phenyl)-5-methyl-hexanoic acid;
- 20 (3S,5S)-3-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid;
- (3S,5S)-3-Aminomethyl-6-(2-chloro-phenyl)-5-methyl-hexanoic acid;
- (3S,5S)-3-Aminomethyl-6-(4-methoxy-phenyl)-5-methyl-hexanoic acid;
- 25 (3S,5S)-3-Aminomethyl-6-(3-methoxy-phenyl)-5-methyl-hexanoic acid;
- (3S,5S)-3-Aminomethyl-6-(2-methoxy-phenyl)-5-methyl-hexanoic acid;
- 30 (3S,5S)-3-Aminomethyl-6-(4-fluoro-phenyl)-5-methyl-hexanoic acid;
- (3S,5S)-3-Aminomethyl-6-(3-fluoro-phenyl)-5-methyl-hexanoic acid;

- (3S,5S)-3-Aminomethyl-6-(2-fluoro-phenyl)-5-methyl-
hexanoic acid;
- (3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(4-chloro-phenyl)-5-methyl-
5 heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(3-chloro-phenyl)-5-methyl-
heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(2-chloro-phenyl)-5-methyl-
heptanoic acid;
- 10 (3S,5R)-3-Aminomethyl-7-(4-methoxy-phenyl)-5-methyl-
heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(3-methoxy-phenyl)-5-methyl-
heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(2-methoxy-phenyl)-5-methyl-
15 heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(4-fluoro-phenyl)-5-methyl-
heptanoic acid;
- (3S,5R)-3-Aminomethyl-7-(3-fluoro-phenyl)-5-methyl-
heptanoic acid;
- 20 (3S,5R)-3-Aminomethyl-7-(2-fluoro-phenyl)-5-methyl-
heptanoic acid;
- (3S,5S)-3-Aminomethyl-5-methyl-hept-6-enoic acid;
- (3S,5R)-3-Aminomethyl-5-methyl-oct-7-enoic acid;
- (3S,5R)-3-Aminomethyl-5-methyl-non-8-enoic acid;
- 25 (E)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid;
- (Z)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid;
- (Z)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid;
- (E)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid;
- (E)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid;
- 30 (Z)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid;
- (Z)-(3S,5R)-3-Aminomethyl-5-methyl-dec-7-enoic acid;
- (E)-(3S,5R)-3-Aminomethyl-5-methyl-undec-7-enoic acid;
- (3S,5S)-3-Aminomethyl-5,6, 6-trimethyl-heptanoic acid;

- 5 (3S,5S)-3-Aminomethyl-5,6-dimethyl-heptanoic acid;
 (3S,5S)-3-Aminomethyl-5-cyclopropyl-hexanoic acid;
 (3S,5S)-3-Aminomethyl-5-cyclobutyl-hexanoic acid;
 (3S,5S)-3-Aminomethyl-5-cyclopentyl-hexanoic acid;
 (3S,5S)-3-Aminomethyl-5-cyclohexyl-hexanoic acid;
 (3S,5R)-3-Aminomethyl-5-methyl-8-phenyl-octanoic acid;
 (3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;
 (3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid;
 (3R,4R,5R)-3-Aminomethyl-4,5-dimethyl-heptanoic acid; and
 10 (3R,4R,5R)-3-Aminomethyl-4,5-dimethyl-octanoic acid.

38. The method according to Claim 1, wherein the $\alpha_2\delta$ ligand is a compound of Formula (IXA) or Formula (IXB)



or a pharmaceutically acceptable salt thereof wherein:

15 n is an integer of from 0 to 2;

R is sulfonamide,

amide,


phosphonic acid,

heterocycle,

20 sulfonic acid, or

hydroxamic acid;

A is hydrogen or methyl; and



straight or branched alkyl of from 1 to 11 carbons, or
 $-(CH_2)_{1-4}-Y-(CH_2)_{0-4}$ -phenyl wherein Y is -O-, -S-, -NR'₃
 wherein


R'₃ is alkyl of from 1 to 6 carbons, cycloalkyl of from 3 to
 8 carbons, benzyl or phenyl wherein benzyl or phenyl can
 be unsubstituted or substituted with from 1 to 3 substituents
 each independently selected from alkyl, alkoxy, halogen,
 hydroxy, carboxy, carboalkoxy, trifluoromethyl, and nitro.

5


39. The method according to Claim 38, wherein R is a sulfonamide selected
 10 from -NHSO₂R¹⁵ and -SO₂NHR¹⁵, wherein R¹⁵ is straight or branched
 alkyl or trifluoromethyl.

40. The method according to Claim 38, wherein R is a phosphonic acid,
 -PO₃H₂.

41. The method according to Claim 38, wherein R is



42. The method according to Claim 38, wherein R is




43. The method according to Claim 38, wherein the compound of
 Formulas (IXA) or (IXB) is selected from:

20

4-Methyl-2-(1H-tetrazol-5-ylmethyl)-pentylamine;

- 3-(2-Aminomethyl-4-methyl-pentyl)-4H-[1,2,4]oxadiazole-5-thione, HCl;
 (2-Aminomethyl-4-methyl-pentyl)-phosphonic acid;
 3-(3-Amino-2-cyclopentyl-propyl)-4H-[1,2,4]oxadiazol-5-one;
 3-(3-Amino-2-cyclopentyl-propyl)-4H-[1,2,4]thiadiazol-5-one;
 5 2-Cyclopentyl-3-(2-oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-yl)-
 propylamine;
 3-(3-Amino-2-cyclobutyl-propyl)-4H-[1,2,4]oxadiazol-5-one;
 3-(3-Amino-2-cyclobutyl-propyl)-4H-[1,2,4]thiadiazol-5-one; and
 2-Cyclobutyl-3-(2-oxo-2,3-dihydro-2λ⁴-[1,2,3,5]oxathiadiazol-4-yl)-
 10 propylamine.
44. The method according to Claim 38, wherein the alpha2delta ligand is 3-(2-aminomethyl-4-methyl-pentyl)-4H-[1,2,4]oxadiazol-5-one.
45. The method according to Claim 38, wherein the alpha2delta ligand is 3-(2-aminomethyl-4-methyl-pentyl)-4H-[1,2,4]-oxadiazol-5-one hydrochloride.
- 15 46. The method according to Claim 1, wherein the alpha2delta ligand is a compound of the Formula V, VI, VII, or VIII




- or pharmaceutically acceptable salt thereof,
 wherein n is an integer of from 1 to 4, and
 20 where there are stereocenters, each center may be independently R or S.
47. The method according to Claim 46, wherein n is an integer of from 2 to 4.

48. The method according to Claim 46, wherein the $\alpha_2\delta$ ligand is a compound of the Formula V.
49. The method according to Claim 46, wherein the $\alpha_2\delta$ ligand is selected from:
- 5 (1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;
(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid; (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid; (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; and
10 (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid.
50. The method according to Claim 46, wherein the $\alpha_2\delta$ ligand is selected from:
- (1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
15 (1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
20 (1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 α ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
25 (1 α ,6 α ,8 α)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 α)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,

- (1 α ,3 β ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
 (1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
 (1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
 ((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 5 ((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 ((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 ((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]oct-3-yl)-acetic acid,
 ((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 10 ((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 15 ((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 20 ((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)acetic
 acid,
 ((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)
 acetic acid,
 ((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)
 25 acetic acid,
 ((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)
 acetic acid,
 ((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 30 ((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 ((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
 ((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,

- 5 ((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
 ((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
 ((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-
 acetic acid,
10 ((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
 ((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-
 acetic acid,
15 ((2S,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-
 acetic acid,
 ((2S,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-
 acetic acid, and
 ((2R,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-
20 acetic acid.
51. The method according to Claim 46, wherein the $\alpha_2\delta$ ligand is
 (1 α ,3 α ,5 α)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid.
52. The method according to Claim 46, wherein the $\alpha_2\delta$ ligand is
 (1 α ,3 α ,5 α)(3-aminomethyl-bicyclo[3.2.0.]hept-3-yl)-acetic acid
25 hydrochloride.

53. The method according to Claim 1, wherein the $\alpha_2\delta$ ligand is a compound of the Formula (XII) or (XIII)



or a pharmaceutically acceptable salt thereof wherein:

5 n is an integer of from 0 to 2;

R is sulfonamide,

amide,

phosphonic acid,

heterocycle,

10 sulfonic acid, or

hydroxamic acid; and

X is -O-, -S-, -S(O)-, -S(O)₂-, or NR'₁ wherein R'₁ is hydrogen, straight or

branched alkyl of from 1 to 6 carbons, benzyl, -C(O)R'₂ wherein

R'₂ is straight or branched alkyl of 1 to 6 carbons, benzyl or phenyl


15 or -CO₂R'₃ wherein R'₃ is straight or branched alkyl of from 1 to

6 carbons, or benzyl wherein the benzyl or phenyl groups can be

unsubstituted or substituted by from 1 to 3 substituents selected

from halogen, trifluoromethyl, and nitro.


- 20 54. The method according to Claim 1, wherein the $\alpha_2\delta$ ligand is a compound of the Formula



or a pharmaceutically acceptable salt thereof wherein:

R is hydrogen or lower alkyl;

R₁ is hydrogen or lower alkyl;



5 straight or branched alkyl of from 7 to 11 carbon atoms, or


$\text{---}(\text{CH}_2)_{(1-4)}\text{---X---}(\text{CH}_2)_{(0-4)}\text{---phenyl}$ wherein

X is ---O--- , ---S--- , $\text{---NR}_3\text{---}$ wherein


R₃ is alkyl of from 1 to 6 carbons, cycloalkyl of from 3 to 8 carbons, benzyl or phenyl;

10 wherein phenyl and benzyl can be unsubstituted or substituted with from 1 to 3 substituents each independently selected from alkyl, alkoxy, halogen, hydroxy, carboxy, carboalkoxy, trifluoromethyl, amino, and nitro.


15 55. The method according to Claim 1, wherein the $\alpha_2\delta$ ligand is a compound of the Formula (1), (2), (3), (4), (5), (6), (7), or (8)




(1)




(2)




(3)




(4)



(5)



(6)



or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein:

R₁ to R₁₀ are each independently selected from hydrogen or a straight or

branched alkyl of from 1 to 6 carbons, benzyl, or phenyl;

5 m is an integer of from 0 to 3;

n is an integer of from 1 to 2;

o is an integer of from 0 to 3;

p is an integer of from 1 to 2;

q is an integer of from 0 to 2;

10 r is an integer of from 1 to 2;

s is an integer of from 1 to 3;

t is an integer of from 0 to 2; and

u is an integer of from 0 to 1.